Verastem Inc VSTM

$8.18 -0.26 (-3.08%)

Valuation

Market cap
1,030,803,000
Revenue TTM
$30,910,000
Net income TTM
$-209,470,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-677.68%
Debt to equity
11.82

Trading

Volume
1,721,400
Avg volume
3,841,216
Day's range
$7.98 – $8.40
Shares out
126,015,000
Stochastic %K
19%
Beta
0.45
Analysts
Strong Buy
Price target
$17.22

Price

Company profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway t...

Show more

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 292 4200
Website
https://www.verastem.com
Address
117 Kendrick Street, Suite 500, Needham, United States

Latest news

Stocktwits

CrozrX Nov 15, 6:25 PM
$VSTM Defactinib and avutometinib AEMS report, like the one for daraxonrasib down below
1 replies
CrozrX Nov 15, 6:08 PM
$VSTM Made an attempt to extrapolate off label use for defactinib and avutometinib from AEMS FDA site. FDA AEMS reports were analyzed to characterize the frequency, distribution and temporal evolution of reported off-label use of avutometinib + defactinib. While inherently limited and not a measure of prescribing volume, these data offer directional insight into physician-directed utilization and the diversification of reported indications beyond the approved LGSOC setting. The broader question is how this landscape may evolve with the expanding adoption of KRAS-targeted therapies, the growing need to address disease progression following KRAS inhibition, and the maturing clinical data from RAMP 205 and other complementary combination strategies.
0 replies
CrozrX Nov 15, 7:23 AM
$VSTM $RVMD Patient fitness remains one of the most precious and rapidly depleting resources in PDAC. The availability of increasingly effective therapies does not eliminate line-to-line attrition. Their clinical value depends not only on controlling disease but also on preserving the physiological reserve necessary to sustain treatment and access subsequent therapeutic opportunities. The attrition curve deserves attention alongside the survival curve.
1 replies
Merlintrader Nov 14, 7:57 PM
$VSTM Nov 5: Verastem reported September cash and investments of 172.8 million dollars and company-stated pro forma resources of 422.8 million dollars including the October offering’s gross proceeds. It expects runway into 1H 2028 and initial VS-7375 plus cetuximab pancreatic-cancer data in early 2027. Not investment advice. Full context in our $VSTM stock hub: https://www.merlintrader.com/verastem-oncology-vstm-stock-hub/
1 replies
Robertbuote Nov 14, 3:55 AM
$VSTM https://www.reuters.com/world/us-fda-shelves-commissioners-voucher-program-speedy-drug-reviews-sources-say-2026-11-12/
1 replies
sweddle Nov 14, 12:54 AM 0 replies
OTW224 Nov 13, 11:10 PM
$VSTM well this has been a shit sandwich for over a week. But after 6-7 years who’s not surprised. Nobody gives Verastem respect.
0 replies
CrozrX Nov 13, 5:53 PM 2 replies